Navigation Links
GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
Date:7/13/2009

LAS VEGAS, July 13 /PRNewswire-FirstCall/ -- GNC, the leading global specialty retailer of nutritional products, announced today clinical results for the first and only nitric oxide product, Amplified Maxertion N.O., proven to demonstrate a delay in the onset of neuromuscular fatigue. The key findings were unveiled at the National Strength and Conditioning Association (NSCA) conference in Las Vegas, NV.

GNC's Amplified Maxertion N.O.(TM) was shown to increase power output at the onset of neuromuscular fatigue by an average of 20% and improve physical performance by helping athletes push past their normal point of exhaustion. This product is designed to increase nitric oxide levels in the body causing a hemodilation effect which expands blood vessels, allowing more blood, oxygen and nutrients to flow to muscles.

"This is truly groundbreaking research that has resulted in the delivery of a truly novel and clinically-validated product to the industry," said Guru Ramanathan, SVP Technology and Product Innovation for GNC. "Using advanced technology and ingredients, this is the first Nitric Oxide enhancing product to demonstrate significant athletic performance effects that are relevant and meaningful to all types of athletes."

The purpose of the double-blind placebo-controlled study was to examine the effects of daily administration of arginine-based supplements on the physical working capacity at the fatigue threshold (PWC(FT)). The PWC(FT) test estimates the highest power output that can be maintained without neuromuscular evidence of fatigue.

Using a cycle ergometer (stationary bicycle), all subjects performed an incremental test to exhaustion prior to supplementation and after four weeks of supplementation. Key study findings demonstrate significant mean increases in PWC(FT) for the 1.5 gm (22.4%) and 3.0 gm (18.8%) supplement groups, but no change for the placebo group (-1.6%).

The study followed 50 college-aged males over the course of four weeks who were randomized into one of three groups - a. placebo (microcrystalline cellulose), b. 1.5 gm of micronized arginine and 300 mg of grape seed extract, and c. 3.0 gm of micronized arginine and 300 mg of grape seed extract.

Amplified Maxertion N.O. is part of a comprehensive line of eight new advanced muscle performance and sports nutrition products from GNC. The entire Pro Performance(R) AMP line was developed through rigorous clinical research and is designed to suit the needs of a wide range of dedicated athletes, from the weekend warrior to the ultra competitive athlete.

About GNC

GNC, headquartered in Pittsburgh, Pa., is the largest global specialty retailer of nutritional products including vitamin, mineral, herbal and other specialty supplements and sports nutrition, diet and energy products. As of March 31, 2009, GNC has more than 5,200 retail locations throughout the United States (including 944 franchise and 1,733 Rite Aid store-within-a-store locations) and franchise operations in 44 international markets. The company -- which is dedicated to helping consumers Live Well -- also offers products and product information online at www.gnc.com.


'/>"/>
SOURCE GNC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oregon Tourism Commission Unveils New Online Customer Service Training Program
2. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
3. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
4. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
5. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
6. Boehringer Ingelheim Unveils Diabetes Pipeline
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
(Date:6/23/2016)... MEDIA, Pa. , June 23, 2016 ... treatments in an outpatient dialysis facility.  Treatments are usually ... to 6 hours per visit, including travel time, equipment ... on a patient, but especially grueling for patients who ... residents of a skilled nursing and rehabilitation centers for ...
(Date:6/23/2016)... YORK , June 23, 2016 ... waters, but it continues to present great opportunities to ... companies for today: Intrexon Corp. (NYSE: XON ... Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), and ... more about these stocks and receive your complimentary trade ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
Breaking Medicine News(10 mins):